In a recent video interview, interventional radiologist Lindsay Machan, MD, discussed his longtime work with selective salpingography and fallopian tube recanalization to assist women with infertility issues, and key findings from a new study that he recently presented at the Society of Interventional Radiology (SIR) conference.
Could fallopian tube recanalization be a more viable and cost-effective option than assisted fertility procedures such as in vitro fertilization (IVF)?
Lindsay Machan, MD and colleagues have noted intriguing findings in a new study looking at the use of selective salpingography and subsequent fallopian tube recanalization for women with infertility issues. Dr. Machan, an interventional radiologist and associate professor in the Department of Radiology at the University of British Columbia, recently presented the study findings at the Society of Interventional Radiology (SIR) conference in Boston.
In a video interview, Dr. Machan noted that the use of selective salpingography revealed significant tubal disease in nearly 16 percent of the patients in the study. Over 56 percent of the study patients who had unilateral or bilateral fallopian tube blockages were able to undergo fallopian tube recanalization, a simple, half-hour procedure that can be done on an outpatient basis, according to Dr. Machan, an associate professor in the Department of Radiology at the University of British Columbia.
Dr. Machan added that the use of sedation with repeat hysterosalpingogram revealed normal fallopian tubes for nearly 24 percent of women who were previously diagnosed with blockages in one or both fallopian tubes.
Dr. Machan has studied and performed selective salpingography and fallopian tube recanalization procedures for over three decades. While the procedures are not new, Dr. Machan said he is hopeful that findings from the new study, reportedly the largest study (involving 956 women) to date on these procedures, will increase the awareness and utilization of these procedures for woman with infertility issues.
For additional insights from Dr. Machan, watch the video below:
Current Insights and Emerging Roles for Contrast-Enhanced Mammography
May 10th 2024In a recent lecture at the 2024 ARRS Annual Meeting, Jordana Phillips, MD, discussed the role of contrast-enhanced mammography in staging breast cancer, evaluating response to neoadjuvant chemotherapy and recalls from screening.
Could a Newly FDA-Cleared C-Arm Device Bolster Efficiency for Interventional Radiologists?
April 22nd 2024In addition to advanced imaging quality and dose efficiency, the Philips Zenition 30 mobile C-arm device emphasizes personalized user profiles and automated customization to help reduce procedure time.